KBY Biotech Indexv0.0.34
Search
← Pipeline|CHA-IIT-901

CHA-IIT-901

Approved
By Charité Berlin
Source: Trial-derived·Trials: 1
Modality
Gene Editing
MOA
KRASG12Di
Target
SMN2
Pathway
DDR
PAH
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
~May 2019
→ ~Aug 2020
Phase 2
~Nov 2020
→ ~Feb 2022
Phase 3
~May 2022
→ ~Aug 2023
NDA/BLA
~Nov 2023
→ ~Feb 2025
Approved
May 2025
→ Oct 2029
ApprovedCurrent
NCT03871162
558 pts·PAH
2025-05→2029-10·Terminated
558 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-10-163.5y awayPh3 Readout· PAH
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Termina…
Catalysts
Ph3 Readout
2029-10-16 · 3.5y away
PAH
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03871162ApprovedPAHTerminated558OS
Competitors (10)
DrugCompanyPhaseTargetMOA
DoxarasimodMerck & CoNDA/BLAFGFRKRASG12Di
ZanusertibAbbVieApprovedPCSK9KRASG12Di
PexarelsinAstraZenecaPhase 1DLL3KRASG12Di
NVO-6275Novo NordiskPhase 1SMN2BTKi
IvotuximabGSKNDA/BLAGIP-RKRASG12Di
TAK-5300TakedaPhase 1SMN2AuroraAi
GIL-2259Gilead SciencesApprovedSMN2CAR-T CD19
REG-647RegeneronPreclinicalSMN2SOS1i
TerarasimodKrystal BiotechPhase 1/2PI3KαKRASG12Di
OlpafutibatinibImmunocoreApprovedSMN2Menini